ConductScience.org, home

Paper23882157

NY-ESO-1-specific immunological pressure and escape in a patient with metastatic melanoma.

von Boehmer L and 12 others. Cancer Immun, 2013. Cited by 24 papers, by iCite.

Cite this record

ConductScience Library. NY-ESO-1-specific immunological pressure and escape in a patient with metastatic melanoma. Papers, record 23882157. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/23882157

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
NY-ESO-1-specific immunological pressure and escape in a patient with metastatic melanoma.
PubMed
Journal
Cancer Immun
PubMed
Year
2013
PubMed
Publication types
Case Reports, Journal Article, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
24
iCite
Relative citation ratio, by iCite
0.52
iCite
Revised in PubMed
2021-10-21
PubMed

Authors13

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1von Boehmer LLotta
2Mattle MMuriel
3Bode PPeter
4Landshammer AAlexandro
5Schäfer CCarolin
6Nuber NNatko
7Ritter GGerd
8Old LLloyd
9Moch HHolger
10Schäfer NNiklaus
11Jäger EElke
12Knuth AAlexander
13van den Broek MMaries

Source PubMed

Download CSV of authors

Topics7

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Antigens, NeoplasmMajor topic
MelanomaMajor topic
Membrane ProteinsMajor topic
Humans
Immunohistochemistry
Male
Middle Aged

Source PubMed

Download CSV of topics

References30

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
117294444NY-ESO-1 protein expression in primary breast carcinoma and metastases: correlation with CD8+ T-cell and CD79a+ plasmacytic/B-cell infiltration.Int J Cancer2007https://conductscience.org/library/papers/17294444PubMed
217008531Type, density, and location of immune cells within human colorectal tumors predict clinical outcome.Science2006https://conductscience.org/library/papers/17008531PubMed
37895156Enhanced in vivo growth and resistance to rejection of tumor cells expressing dominant negative IFN gamma receptors.Immunity1994https://conductscience.org/library/papers/7895156PubMed
411027314Induction of primary NY-ESO-1 immunity: CD8+ T lymphocyte and antibody responses in peptide-vaccinated patients with NY-ESO-1+ cancers.Proc Natl Acad Sci U S A2000https://conductscience.org/library/papers/11027314PubMed
59139833Immunoselection in vivo: independent loss of MHC class I and melanocyte differentiation antigen expression in metastatic melanoma.Int J Cancer1997https://conductscience.org/library/papers/9139833PubMed
619381944Autoantibodies against cancer antigens.Methods Mol Biol2009https://conductscience.org/library/papers/19381944PubMed
710502728Humoral immune responses of cancer patients against "Cancer-Testis" antigen NY-ESO-1: correlation with clinical events.Int J Cancer1999https://conductscience.org/library/papers/10502728PubMed
817652518Vaccination with an NY-ESO-1 peptide of HLA class I/II specificities induces integrated humoral and T cell responses in ovarian cancer.Proc Natl Acad Sci U S A2007https://conductscience.org/library/papers/17652518PubMed
921754986MAGE-C2/CT10 protein expression is an independent predictor of recurrence in prostate cancer.PLoS One2011https://conductscience.org/library/papers/21754986PubMed
109618514Identification of multiple cancer/testis antigens by allogeneic antibody screening of a melanoma cell line library.Proc Natl Acad Sci U S A1998https://conductscience.org/library/papers/9618514PubMed
1121436444Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion.Science2011https://conductscience.org/library/papers/21436444PubMed
1210781081Monitoring CD8 T cell responses to NY-ESO-1: correlation of humoral and cellular immune responses.Proc Natl Acad Sci U S A2000https://conductscience.org/library/papers/10781081PubMed
1318026089Adaptive immunity maintains occult cancer in an equilibrium state.Nature2007https://conductscience.org/library/papers/18026089PubMed
149636188Demonstration of an interferon gamma-dependent tumor surveillance system in immunocompetent mice.Proc Natl Acad Sci U S A1998https://conductscience.org/library/papers/9636188PubMed
1512445278Cancer/testis antigens: an expanding family of targets for cancer immunotherapy.Immunol Rev2002https://conductscience.org/library/papers/12445278PubMed
1615252201Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad integrated antibody and CD4(+) and CD8(+) T cell responses in humans.Proc Natl Acad Sci U S A2004https://conductscience.org/library/papers/15252201PubMed
1718833002Immune responses detected in urothelial carcinoma patients after vaccination with NY-ESO-1 protein plus BCG and GM-CSF.J Immunother2008https://conductscience.org/library/papers/18833002PubMed
1817944437LUD 00-009: phase 1 study of intensive course immunization with NY-ESO-1 peptides in HLA-A2 positive patients with NY-ESO-1-expressing cancer.Cancer Immun2007https://conductscience.org/library/papers/17944437PubMed
1911323675IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity.Nature2001https://conductscience.org/library/papers/11323675PubMed
2016984998Recombinant vaccinia/fowlpox NY-ESO-1 vaccines induce both humoral and cellular NY-ESO-1-specific immune responses in cancer patients.Proc Natl Acad Sci U S A2006https://conductscience.org/library/papers/16984998PubMed

See all 30 referencesDownload CSV of references

Cited by14

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 24 citations.

PMIDTitleJournalYearIn PapersSource
42568362Overcoming immunotherapy barriers in pediatric brain tumors: epigenetic strategies.Front Oncol2026https://conductscience.org/library/papers/42568362PubMed
42230788Hallmarks and correlates of effective adoptive cell immunotherapy for cancer.Nat Rev Immunol2026https://conductscience.org/library/papers/42230788PubMed
37731507Current advances in cancer vaccines targeting NY-ESO-1 for solid cancer treatment.Front Immunol2023https://conductscience.org/library/papers/37731507PubMed
36125618Antibody-Drug Conjugates for Melanoma and Other Skin Malignancies.Curr Treat Options Oncol2022https://conductscience.org/library/papers/36125618PubMed
36124553Transient cell-in-cell formation underlies tumor relapse and resistance to immunotherapy.Elife2022https://conductscience.org/library/papers/36124553PubMed
35883486MicroRNAs at the Crossroad between Immunoediting and Oncogenic Drivers in Hepatocellular Carcinoma.Biomolecules2022https://conductscience.org/library/papers/35883486PubMed
32220256Unleashing the immune response to NY-ESO-1 cancer testis antigen as a potential target for cancer immunotherapy.J Transl Med2020https://conductscience.org/library/papers/32220256PubMed
31492199Tumor neoantigens: from basic research to clinical applications.J Hematol Oncol2019https://conductscience.org/library/papers/31492199PubMed
31413920Acquired resistance during adoptive cell therapy by transcriptional silencing of immunogenic antigens.Oncoimmunology2019https://conductscience.org/library/papers/31413920PubMed
30233579Turn Back the TIMe: Targeting Tumor Infiltrating Myeloid Cells to Revert Cancer Progression.Front Immunol2018https://conductscience.org/library/papers/30233579PubMed
28534024Cancer Immunoprevention and Public Health.Front Public Health2017https://conductscience.org/library/papers/28534024PubMed
26241053From mice to humans: developments in cancer immunoediting.J Clin Invest2015https://conductscience.org/library/papers/26241053PubMed
24531241New insights into cancer immunoediting and its three component phases--elimination, equilibrium and escape.Curr Opin Immunol2014https://conductscience.org/library/papers/24531241PubMed
24349875HLA-DR expression on myeloid cells is a potential prognostic factor in patients with high-risk neuroblastoma.Oncoimmunology2013https://conductscience.org/library/papers/24349875PubMed

Download CSV of cited by

Genes4

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
CD4920PubTator's text mininghttps://conductscience.org/library/genes/920NCBI Gene
CTAG1A246100PubTator's text mininghttps://conductscience.org/library/genes/246100NCBI Gene
MAGEC19947PubTator's text mininghttps://conductscience.org/library/genes/9947NCBI Gene
MLANA2315PubTator's text mininghttps://conductscience.org/library/genes/2315NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/23882157

GET https://conductscience.org/api/papers/v1/23882157/references?page=2